Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036572 (
seizures
)
80,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study has been designed to pharmacologically investigate the effect of
Montelukast sodium
, a leukotriene D(4) receptor antagonist, and 1,2,3,4, tetrahydroisoquinoline, a leukotriene D(4) synthetic pathway inhibitor, on the pathophysiological progression of
seizures
using mouse models of kindled epilepsy and status epilepticus induced spontaneous recurrent
seizures
. Pentylenetetrazole (40 mg kg(-1)) (PTZ) administration every second day for a period of 15 d was used to elicit chemically induced kindled
seizure
activity in mice. In a separate set of groups, fifty consecutive electroshocks were delivered to mice using corneal electrodes with continuously increasing intensity with an inter-shock interval of 40s. Severity of kindled
seizures
was assessed in terms of a composite kindled
seizure
severity score (KSSS). Pilocarpine (100 mg kg(-1)) was injected every twenty minutes until the onset of status epilepticus. A spontaneous recurrent
seizure
severity score (SRSSS) was recorded as a measure of quantitative assessment of the progressive development of spontaneous recurrent
seizures
induced after pilocarpine status epilepticus. Sub-acute PTZ administration and electroshock induced the development of severe form of kindled
seizures
in mice. Severity of kindled
seizures
was assessed in terms of a composite kindled
seizure
severity score. Further, pharmacological status epilepticus elicited a progressive evolution of spontaneous recurrent
seizures
in the animals. However,
Montelukast sodium
, a leukotriene D(4) receptor antagonist, as well as 1,2,3,4, tetrahydroisoquinoline, a leukotriene D(4) synthetic pathway inhibitor, markedly and dose dependently suppressed the development of kindled
seizures
as well as pilocarpine induced spontaneous recurrent
seizures
. Therefore, leukotriene D(4) may be implicated in the pathogenesis of
seizures
.
...
PMID:Modulation of leukotriene D4 attenuates the development of seizures in mice. 2164 Nov 95